Referências Bibliográficas Úteis

01. Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann. Oncol. 16(3), 352–358 (2005).  02. Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm. Res. 23(11), 2505–2514 (2006). 03. Batchelor D. Hair and cancer chemotherapy: consequences and nursing care – a literature study. Eur. J. Cancer Care (Engl.). 10(3), 147–163 (2001). 04. Trueb RM. Chemotherapy-induced alopecia. Semin. Cutan. Med. Surg. 28(1), 11–14 (2009). 05. Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support. Care Cancer. 12(8), 543–549 (2004). 06. Karakunnel J, Berger AM. Hair loss. In: Cancer: Principles & Practice of Oncology (8th Edition). Lippincott Williams & Wilkins, PA, USA, 2688–2691 (2008). 07. Bleiker TO, Nicolaou N, Traulsen J, Hutchinson PE. 'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans. Br. J. Dermatol. 153(1), 103–112 (2005). 08. Sinclair R. Diffuse hair loss. Int. J. Dermatol. 38(Suppl. 1), 8–18 (1999). 09. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Abeloff's Clinical Oncology, 4th Edition. Churchill Livingstone, NY, USA, 626–627 (2008). 10. Clement-Jones V. Cancer and beyond: the formation of BACUP. BMJ 291(6501), 1021–1023 (1985). 11. Yun SJ, Kim SJ. Hair loss pattern due to chemotherapy-induced anagen effluvium: a cross-sectional observation. Dermatology (1), 36–40 (2007). 12. Crounse RG, Van Scott EJ. Changes in scalp hair roots as a measure of toxicity from cancer chemotherapeutic drugs. J. Invest. Dermatol. 35, 83–90 (1960). 13. Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol. Med. 7(7), 293–301 (2001). 14. Paus R, Cotsarelis G. The biology of hair follicles. N. Engl. J. Med. 341(7), 491–497 (1999). 15. Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J. Am. Acad. Dermatol. 63(2), 333–336 (2009). 16. Hussein AM. Chemotherapy-induced alopecia: new developments. South. Med. J. 86(5), 489–496 (1993). 17. Pickard-Holley S. The symptom experience of alopecia. Semin. Oncol. Nurs. 11(4), 235–238 (1995). 18. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol. 17(6), 935–944 (2006). 19. Baker BW, Wilson CL, Davis AL et al. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth. Bone Marrow Transplant. 7(1), 43–47 (1991). 20. Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am. J. Med. Sci.321(5), 327–335 (2001). 21. de Jonge ME, Mathot RA, Dalesio O, Huitema AD, Rodenhuis S, Beijnen JH. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant. 30(9), 593–597 (2002). 22. Machado M, Moreb JS, Khan SA. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant. 40(10), 979–982 (2007). 23. Tosti A, Piraccini BM, Vincenzi C, Misciali C. Permanent alopecia after busulfan chemotherapy. Br. J. Dermatol. 152(5), 1056–1058 (2005). 24. Tran D, Sinclair RD, Schwarer AP, Chow CW. Permanent alopecia following chemotherapy and bone marrow transplantation. Australas. J. Dermatol. 41(2), 106–108 (2000). 25. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant.15(6), 869–871 (1995). 26. Vowels M, Chan LL, Giri N, Russell S, Lam-Po-Tang R. Factors affecting hair regrowth after bone marrow transplantation. Bone Marrow Transplant. 12(4), 347–350 (1993). 27. Prevezas C, Matard B, Pinquier L, Reygagne P. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br. J. Dermatol. 160(4), 883–885 (2009). 28. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 84(7), 2144–2150 (1994). 29. Dougherty L. Scalp cooling to prevent hair loss in chemotherapy. Prof. Nurse 11(8), 507–509 (1996). 30. Lenaerts E, Meyen M, Maes T et al. Scalp cooling in the prevention of anthracycline-induced alopecia. Eur. J. Cancer 37(Suppl. 6), 360 (2001). 31. Tierney A, Taylor J. Chemotherapy-induced hair loss. Nurs. Stand. 5(38), 29–31 (1991). 32. van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 19(7), 701–709 (2010). 33. Auvinen PK, Mahonen UA, Soininen KM et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 96(2), 271–275 (2010). 34. Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP. Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support. Care Cancer17(2), 181–189 (2009). 35. Helms RL, O'Hea EL, Corso M. Body image issues in women with breast cancer. Psychol. Health Med. 13(3), 313–325 (2008). 36. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17(4), 317–328 (2008). 37. Baxley KO, Erdman LK, Henry EB, Roof BJ. Alopecia: effect on cancer patients' body image. Cancer Nurs. 7(6), 499–503 (1984). 38. Fobair P, Stewart SL, Chang S, D'Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology 15(7), 579–594 (2006). 39. Forrest G, Plumb C, Ziebland S, Stein A. Breast cancer in the family – children's perceptions of their mother's cancer and its initial treatment: qualitative study. BMJ 332(7548), 998–1003 (2006). 40. Tierney AJ, Taylor J, Closs SJ. Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer. Scand. J. Caring Sci. 6(2), 75–80 (1992). 41. Dean JC, Salmon SE, Griffith KS. Prevention of doxorubicin-induced hair loss with scalp hypothermia. N. Engl. J. Med. 301(26), 1427–1429 (1979). 42. Williams J, Wood C, Cunningham-Warburton P. A narrative study of chemotherapy-induced alopecia. Oncology Nurs. Forum 26(9), 1463–1468 (1999). 43. McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract. 9(6), 283–293 (2001). 44. Mulders M, Vingerhoets A, Breed W. The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians. Eur. J. Oncol. Nurs. 12(2), 97–102 (2008). 45. Kufe D, Bast RC, Hait W et al. Holland-Frei Cancer Medicine 7th Edition. BC Decker Inc, PA, USA, 2077–2085 (2007). 46. Jimenez JJ, Yunis AA. Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3. Cancer Res. 52(18), 5123–5125 (1992). 47. Karakunnel JJ, Berger AM. Hair loss. In: Cancer. Principles & Practice of Oncology. 8th Edition. DeVita V, Lawrence W, Rosenberg S (Eds). Lippincott Williams & Wilkins, PA, USA, 2688–2691 (2008). 48. Balsari AL, Morelli D, Menard S, Veronesi U, Colnaghi MI. Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J. 8(2), 226–230 (1994). 49. Metz JM, Smith D, Mick R et al. A Phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin. Cancer Res. 10(19), 6411–6417 (2004). 50. Hussein AM. Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Int. J. Dermatol. 34(7), 470–473 (1995). 51. Duvic M, Lemak NA, Valero V et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J. Am. Acad. Dermatol. 35(1), 74–78 (1996). 52. Rodriguez R, Machiavelli M, Leone B et al. Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Ann. Oncol. 5(8), 769–770 (1994). 53. Hennessey JD. Alopecia and cytotoxic drugs. BMJ 2, 1138 (1966). 54. Pesce A, Cassuto JP, Joyner MV, DuJardin P, Audoly P. Scalp tourniquet in the prevention of chemotherapy-induced alopecia. N. Engl. J. Med. 298(21), 1204–1205 (1978). 55. Benjamin B, Ziginskas D, Harman J, Meakin T. Pulsed electrostatic fields (ETG) to reduce hair loss in women undergoing chemotherapy for breast carcinoma: a pilot study. Psychooncology 11(3), 244–248 (2002). 56. Bulow J, Friberg L, Gaardsting O, Hansen M. Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man. Scand. J. Clin. Lab. Invest.45(6), 505–508 (1985). 57. Ron IG, Kalmus Y, Kalmus Z, Inbar M, Chaitchik S. Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. Support. Care Cancer 5(2), 136–138 (1997). 58. Hillen HF, Breed WP, Botman CJ. Scalp cooling by cold air for the prevention of chemotherapy-induced alopecia. Neth. J. Med. 37(5–6), 231–235 (1990). 59. Cohen B. The cross-section trichometer: a new device for measuring hair quantity, hair loss, and hair growth. Dermatol. Surg. 34(7), 900–910; discussion 10–11 (2008). 60. Edelstyn GA, MacDonald M, MacRae KD. Doxorubicin-induced hair loss and possible modification by scalp cooling. Lancet 2(8031), 253–254 (1977). 61. Giaccone G, Di Giulio F, Morandini MP, Calciati A. Scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer Nurs. 11(3), 170–173 (1988). 62. Kennedy M, Packard R, Grant M, Padilla G, Presant C, Chillar R. The effects of using Chemocap on occurrence of chemotherapy-induced alopecia. Oncol. Nurs. Forum 10(1), 19–24 (1983). 63. Macduff C, Mackenzie T, Hutcheon A, Melville L, Archibald H. The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel. Eur. J. Cancer Care (Engl.) 12(2), 154–161 (2003). 64. Parker R. The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia. Oncol. Nurs. Forum 14(6), 49–53 (1987). 65. Satterwhite B, Zimm S. The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer 54(1), 34–37 (1984). 66. Spaeth D, Luporsi E, Weber B et al. Efficacy and safety of cooling helmets (CH) for the prevention of chemotherapy-induced alopecia (CIA): a prospective study of 911 patients (pts). J. Clin. Oncol. 26(20 Suppl.), 9564 (2008). 67. Lemenager M, Lecomte S, Bonneterre ME, Bessa E, Dauba J, Bonneterre J. Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur. J. Cancer 33(2), 297–300 (1997). 68. Belpomme D, Mignot L, Grandjean M et al. Prevention of chemotherapy-induced alopecia in cancer patients by scalp hypothermia. Nouv. Presse Med. 11(12), 929 (1982). 69. van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 19(7), 701–709 (2010). 70. Protiere C, Evans K, Camerlo J et al. Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. Support. Care Cancer 10(7), 529–537 (2002). 71. Villani C, Inghirami P, Pietrangeli D, Tomao S, Pucci G. Prevention by hypothermic cap of antiblastic induced-alopecia. Eur. J. Gynaecol. Oncol. 7(1), 15–17 (1986). 72. Lemenager M, Genouville C, Bessa EH, Bonneterre J. Docetaxel-induced alopecia can be prevented. Lancet 346(8971), 371–372 (1995). 73. Dean JC, Salmon SE, Griffith KS, Cetas TC, Mackel C. Scalp hypothermia: a comparison of ice packs and Kold Kap in the prevention of adriamycin (adr) induced alopecia. Proc. Am. Soc. Clin. Oncol. 22 (1981) (Abstract C324). 74. Gregory RP, Cooke T, Middleton J, Buchanan RB, Williams CJ. Prevention of doxorubicin-induced alopedia by scalp hypothermia: relation to degree of cooling. BMJ 284(6330), 1674 (1982). 75. Robinson MH, Jones AC, Durrant KD. Effectiveness of scalp cooling in reducing alopecia caused by epirubicin treatment of advanced breast cancer. Cancer Treat. Rep. 71(10), 913–914 (1987). 76. Guy R, Shah S, Parker H, Geddes D. Scalp cooling by thermocirculator. Lancet 1(8278), 937–938 (1982). 77. Luce JK, Raffetto TJ, Crisp IM, Grief GC. Prevention of alopecia by scalp cooling of patients receiving adriamycin. Canc. Chemother. Rep. 57(1), 108–109 (1973). 78. Peck HJ, Mitchell H, Stewart AL. Evaluating the efficacy of scalp cooling using the Penguin cold cap system to reduce alopecia in patients undergoing chemotherapy for breast cancer. Eur. J. Oncol. Nurs. 4(4), 246–248 (2000). 79. Lundgren-Eriksson L, Edbom G, Olofsson Y, Ridderheim M, Hendriksson R. Total prevention of taxoid-induced alopecia by a new model of cold cap (dignitana). Eur. J. Cancer 35(Suppl. 4), 376 (1999). 80. Dugan SO. A study on the effects of chemocap in preventing hair loss. Oncol. Nurs. Forum10(2), 20–21 (1983). 81. Kato M, Sakuyama A, Imai R, Kobayashi TK, Okamura M, Asaka I. Scalp-cooling by dignicap system for the prevention of chemotherapy-induced hair loss in breast cancer patients. J. Clin. Oncol. 28 (2010) (Abstract e11034). 82. David J, Speechley V. Scalp cooling to prevent alopecia. Nurs. Times 83(32), 36–37 (1987). 83. Kiser J, Jungi E, Winkler L et al. [Hypothermia: scalp cooling for the prevention of cytostatic-induced hair loss]. Krankenpfl. Soins. Infirm. (12), 29–32 (1982). 84. Stein BN, Kotasek D, Parnis FX et al. Prevention of chemotherapy-induced alopecia by the use of scalp cooling. Proc. Am. Soc. Clin. Oncol. 19 (2000) (Abstract 2477). 85. van den Hurk CJG, Coebergh JWW, Breed WPM, van de Poll-Franse LV, Nortier JWR. Shorter post-infusion cooling time of scalp cooling in the prevention of docetaxel-induced hair loss. Eur. J. Cancer 7(2 Suppl.), 181 (2009). 86. ElGenidi M. Prevention of chemotherapy-induced alopecia by the new digital scalp cooler device. Eur. J. Cancer 37(Suppl. 6), 357 (2001). 87. Massey CS. A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur. J. Oncol. Nurs. 8(2), 121–130 (2004). 88. Benglia M, Jourdan C, Sommier Y. [Use of a cooling helmet in chemotherapy]. Soins.469/470, 17–20 (1986). 89. Barzo P, Molnar L, Bator I, Kovacs B.Possibilities of preventing alopecia after cytostatic therapy]. Orv. Hetil. 133(4), 256 (1992). 90. Goldhirsch A, Kiser J, Joss R et al. Prevention of cytostatic-related hair loss by hypothermia of a hairy scalp using a cooling cap]. Schweiz. Med .Wochenschr. 112(16), 568–571 (1982). 91. Ridderheim M, Bjurberg M, Gustavsson A. Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support. Care Cancer 11(6), 371–377 (2003). 92. Kato M, Sakuyama A, Imai R, Kobayashi TK. Evaluation of the DigniCap system for the prevention of chemotherapy-induced hair loss in breast cancer patients. Presented at: 16th Japanese Breast Cancer Society Meeting. Osaka, Japan, 26–27 September, 2008. 93. Middleton J, Franks D, Buchanan RB, Hall V, Smallwood J, Williams CJ. Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat. Rep. 69(4), 373–375 (1985). 94. Byachov. Profilaxis of alopecia in patients undergoing chemotherapy. Meditsinskaya Caroteka (2006). 95. Katsimbri P, Bamias A, Pavlidis N. Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur. J. Cancer 36(6), 766–771 (2000). 96. Ciambellotti E. Benefits of an hypothermal helmet to reduce alopecia during weekly 4-epi-doxorubicin monochemotherapy in advanced breast cancer. Acta Oncologica 14, 297–299 (1993). 97. Semsek D. Scalp hypothermia for 3 hours reduces alopecia after anthracycline based chemotherapy. Ann. Oncol. 11(Suppl. 4), 154 (2000). 98. Howard N, Stenner RW. An improved 'ice-cap' to prevent alopecia caused by adriamycin (doxorubicin). Br. J. Radiol. 56(672), 963–964 (1983). 99. Kolen B, Van de Laar-Müskens J, Van Helvert R, Van der Heul C, Van Riel A. Hoofdhuidkoeling; de moeite waard. Oncologica 4, 9–13 (2002). 100. Anderson JE, Hunt JM, Smith IE. Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer. BMJ 282(6262), 423–424 (1981). 101. Wills S, Ravipati A, Nguyen M, Dana Z, Jaiyesmim I, Margolis J, Decker D. Scalp hypothermia minimizes alopecia in breast cancer patients receiving non-anthracycline adjuvant chemotherapy. Cancer Res. (69), 5040 (2009). 102. Hunt JM, Anderson JE, Smith IE. Scalp hypothermia to prevent adriamycin-induced hair loss. Cancer Nurs. 5(1), 25–31 (1982). 103. Adams L, Lawson N, Maxted KJ, Symonds RP. The prevention of hair loss from chemotherapy by the use of cold-air scalp-cooling. Eur. J. Cancer Care 1(5), 16–18 (1992). 104. Fiebig HH, Belzer J, Klopfer P et al. Scalp hypothermia for 2 hours prevents alopecia after adriamycin based chemotherapy. Eur. J. Cancer 33(Suppl. 8), S53 (1997). 105. Alexopoulos CG, Cheras P, Pothitos G, Kyrpoglou P. A new technique of scalp cooling in preventing alopecia induced by anticancer chemotherapy. Eur. J. Cancer 35(Suppl. 4), 378 (1999). 106. Dixon-Hughes J. Scalp cooling and cytotoxic drugs. Med. J. Aus. 686 (1984). 107. Cooke T, Gregory RP, Middleton J, Williams C. Prevention of doxorubicin-induced alopecia. BMJ 282(6265), 734–735 (1981). 108. Perevodchikova N, Denisov L, Orel N. [Scalp hypothermia for prevention of alopecia in patients receiving combination chemotherapy including anthracyclines]. Vopr. Onkol. 33, 73–75 (1987). 109. Janssen FE. Modelling physiological and biochemical aspects of scalp cooling. Technical University Eindhoven, Eindhoven (2007). 110. Claessens-van Ooijen AM, Westerterp KR, Wouters L, Schoffelen PF, van Steenhoven AA, van Marken Lichtenbelt WD. Heat production and body temperature during cooling and rewarming in overweight and lean men. Obesity (Silver Spring) 14(11), 1914–1920 (2006). 111. van Ooijen AM, van Marken Lichtenbelt WD, van Steenhoven AA, Westerterp KR. Cold-induced heat production preceding shivering. Br. J. Nutr. 93(3), 387–391 (2005). 112. van Marken Lichtenbelt WD, Daanen HA et al. Evaluation of wireless determination of skin temperature using iButtons. Physiol. Behav. 88(4–5), 489–497 (2006). 113. van Marken Lichtenbelt WD, Frijns AJ, van Ooijen MJ, Fiala D, Kester AM, van Steenhoven AA. Validation of an individualised model of human thermoregulation for predicting responses to cold air. Int. J. Biometeorol. 51(3), 169–179 (2007). 114. Tollenaar RA, Liefers GJ, Repelaer van Driel OJ, van de Velde CJ. Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. Eur. J. Cancer30A(10), 1448–1453 (1994). 115. Klaassen U, Kuhndel K, Bauknecht T et al. Safety and efficacy of TAXOL (paclitaxel) over 3 h in 306 platinum-refractory patients with overian cancer: results of a German Cooperative Study. Eur. J. Cancer 31(Suppl. 6), 105 (1995). 116. Symonds RP, McCormick CV, Maxted KJ. Adriamycin alopecia prevented by cold air scalp cooling. Am. J. Clin. Oncol. 9(5), 454–457 (1986). 117. Vendelbo Johansen L. Scalp hypothermia in the prevention of chemotherapy-induced alopecia. Acta Radiol. Oncol. 24(2), 113–116 (1985). 118. Robbins CR. Chemical and Physical Behavior of Human Hair, 4th Edition. Springer, NY, USA (2001). 119. Hurk van den CJG, Gerrits P, Graat J, Kolen B, Laar van de- Müskens J, Breed WPM. [Positive scalp cooling experiences in three hospitals in The Netherlands. Should it be offered always?] Oncologica 22(3), 162–167 (2005). 120. Witman G, Cadman E, Chen M. Misuse of scalp hypothermia. Cancer Treat. Rep. 65(5–6), 507–508 (1981). 121. Forsberg SA. Scalp cooling therapy and cytotoxic treatment. Lancet 357(9262), 1134 (2001). 122. Christodoulou C, Tsakalos G, Galani E, Skarlos DV. Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention. Ann. Oncol. 17(2), 350 (2006). 123. Lemieux J, Amireault C, Provencher L, Maunsell E. Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res. Treat. 118(3), 547–552 (2009). 124. van de Sande MAE, van den Hurk CJG, Breed WPM, Nortier JWR. [Allow scalp cooling during adjuvant chemotherapy in patients with breast cancer; scalp metastases rarely occur]. Nederlands tijdschrift voor geneeskunde. 1–4 (2010). 125. Krathen RA, Orengo IF, Rosen T. Cutaneous metastasis: a meta-analysis of data. South. Med. J. 96(2), 164–167 (2003). 126. Janssen FPEM, Van Leeuwen GMJ, Steenhoven AA. Numerical simulation of scalp cooling to prevent chemotherapy-induced alopecia. Proceedings of: The ASME-ZSIS International Thermal Science Seminar II, p357–361 (2004). 127. Boot E. [A qualitative study on nursing intervention in patients with hair loss despite scalp cooling]. In Dutch: Een kwalitatief onderzoek naar verpleegkundige interventies bij patienten die ondanks hoofdhuidkoeling bij chemotherapie toch haaruitval krijgen. Havenziekenhuis, Rotterdam. Thesis (2007). 128. Cordova MJ, Giese-Davis J, Golant M et al. Mood disturbance in community cancer support groups. The role of emotional suppression and fighting spirit. J. Psychosom. Res. 55(5), 461–467 (2003). 129. Fallowfield LJ. Behavioural interventions and psychological aspects of care during chemotherapy. Eur. J. Cancer 28A(Suppl. 1), S39–S41 (1992). 130. Frith H, Harcourt D, Fussell A. Anticipating an altered appearance: women undergoing chemotherapy treatment for breast cancer. Eur. J. Oncol. Nurs. 11(5), 385–391 (2007). 131. Holland J, Weiss T. The new standard of quality cancer care: integrating the psychosocial aspects in routine cancer from diagnosis through survivorship. Cancer J. 14(6), 425–428 (2008).